Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Sgen save search
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Published: 2023-01-19 (Crawled : 00:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.55%
H: 1.94%
C: 0.6%
tukysa fda approval cancer her2- her2
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:20) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda cancer
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda license cancer
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
Published: 2022-09-19 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -0.04%
H: 0.91%
C: -1.8%
tukysa fda granted review cancer her2- her2
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Published: 2021-09-20 (Crawled : 22:00) - globenewswire.com
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.26%
H: 7.15%
C: 3.47%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 3.52%
H: 0.73%
C: -0.06%
fda cancer approval
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.4%
H: 0.29%
C: -1.42%
fda fda acceptance cancer license
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Published: 2021-04-19 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.4%
H: 0.29%
C: -1.42%
fda fda acceptance cancer license
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2021-04-09 (Crawled : 21:00) - globenewswire.com
SGEN | $228.74 0.1% 20M
|
Health Technology
| Email alert
Add to watchlist
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
fda cancer license
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2021-02-10 (Crawled : 00:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.57%
H: 0.02%
C: -4.18%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -1.1%
fda cancer license
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.